ResearcherErasmus MCActive in the last 2 years
Aniek E. van Diepen
Matched on ORCID iD 0009-0007-0192-5354; OpenAlex author ID A5116066440. Sources: OpenAlex.
Their work
- Papers
- 10 (first author 5, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 33
2025: 3 papers · 2026: 7 papers
Papers 10
- Prevention of Venous Thromboembolism in Patients With Pancreatic Cancer: A Nationwide Survey. Co-author DOI 10.1002/cam4.72306↗
- The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
- The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. First author DOI 10.1007/s00520-026-10568-3↗
- Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles impacting systemic therapy outcomes. First author DOI 10.1016/j.ejca.2026.116263↗
- Pain prevalence and intensity in advanced pancreatic cancer: a nationwide cohort study. Co-author DOI 10.1097/j.pain.0000000000004059↗
- Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. First author DOI 10.1200/jco-25-01935↗
- CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting. First author DOI 10.3390/cancers18111743↗
- Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: Nationwide population-based … First author DOI 10.1016/j.ejca.2025.115385↗
- REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer. Co-author DOI 10.1038/s41467-025-66092-1↗
- Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
Closest collaborators
The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Judith de Vos‐Geelen · 7 shared papers, 2025–2026 · strength 1.81
- Paper CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting. DOI 10.3390/cancers18111743↗
- Paper The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. DOI 10.1007/s00520-026-10568-3↗
- Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
- Johanna W. Wilmink · 5 shared papers, 2025–2026 · strength 1.27
- Paper The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. DOI 10.1007/s00520-026-10568-3↗
- Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
- Paper Prevention of Venous Thromboembolism in Patients With Pancreatic Cancer: A Nationwide Survey. DOI 10.1002/cam4.72306↗
- Marjolein Y.V. Homs · 5 shared papers, 2025–2026 · strength 1.24
- Paper The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. DOI 10.1007/s00520-026-10568-3↗
- Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
- Paper Prevention of Venous Thromboembolism in Patients With Pancreatic Cancer: A Nationwide Survey. DOI 10.1002/cam4.72306↗
- Casper W.F. van Eijck · 4 shared papers, 2025–2026 · strength 1.10
- Paper CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting. DOI 10.3390/cancers18111743↗
- Paper The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. DOI 10.1007/s00520-026-10568-3↗
- Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
- Merlijn U.J.E. Graus · 4 shared papers, 2025–2026 · strength 0.98
- Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
- Paper Prevention of Venous Thromboembolism in Patients With Pancreatic Cancer: A Nationwide Survey. DOI 10.1002/cam4.72306↗
- Paper Pain prevalence and intensity in advanced pancreatic cancer: a nationwide cohort study. DOI 10.1097/j.pain.0000000000004059↗
- Casper H.J. van Eijck · 3 shared papers, 2025–2026 · strength 0.83
- Paper CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting. DOI 10.3390/cancers18111743↗
- Paper The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. DOI 10.1007/s00520-026-10568-3↗
- Paper REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in meta… DOI 10.1038/s41467-025-66092-1↗
- Hanneke W.M. van Laarhoven · 3 shared papers, 2025–2026 · strength 0.71
- Paper Prevention of Venous Thromboembolism in Patients With Pancreatic Cancer: A Nationwide Survey. DOI 10.1002/cam4.72306↗
- Paper Pain prevalence and intensity in advanced pancreatic cancer: a nationwide cohort study. DOI 10.1097/j.pain.0000000000004059↗
- Paper Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic aden… DOI 10.1016/j.ejca.2025.115385↗
- Songul Kucukcelebi · 2 shared papers, 2025–2026 · strength 0.54
- Lydia G. van der Geest · 2 shared papers, 2025–2026 · strength 0.48
- Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
- Paper Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic aden… DOI 10.1016/j.ejca.2025.115385↗
- Ignace H. J. T. de Hingh · 2 shared papers, 2025–2026 · strength 0.48
- Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
- Paper Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic aden… DOI 10.1016/j.ejca.2025.115385↗
- Stefan A.W. Bouwense · 2 shared papers, 2025–2026 · strength 0.45
- Marc G. Besselink · 2 shared papers, 2025–2026 · strength 0.45
- Anne Margarethe Stiggelbout · 1 shared paper, 2026 · strength 0.29
- Brigitte C.M. Haberkorn · 1 shared paper, 2026 · strength 0.29
- Gaby J. Strijk · 1 shared paper, 2026 · strength 0.29
- Jeanin Elise van Hooft · 1 shared paper, 2026 · strength 0.27
- Thijmen H.T. Broekman · 1 shared paper, 2026 · strength 0.27
- Ruth A.L. Willems · 1 shared paper, 2026 · strength 0.26
- Nick van Es · 1 shared paper, 2026 · strength 0.26
- Hugo ten Cate an · 1 shared paper, 2026 · strength 0.26
- Simone Augustinus · 1 shared paper, 2026 · strength 0.24
- Pauline A. J. Vissers · 1 shared paper, 2026 · strength 0.24
- Nigel G. Kooreman · 1 shared paper, 2026 · strength 0.24
- Anne M. Gehrels · 1 shared paper, 2026 · strength 0.24
- Lois A. Daamen · 1 shared paper, 2025 · strength 0.21
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.